Clinical trial
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects…
NCT00061646 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00061646 |
|---|---|
| Title | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Abbott, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | ABT-510/Thrombospondin-1 mimetic, Carboplatin/Taxol |
| Enrollment | 25 |
| Start date | Mar 1, 2003 |
| First posted | Jun 4, 2003 |
| Last update posted | Aug 14, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: